Filing Flows › Health Care › Scilex Holding (SCLX)
Scilex Holding (SCLX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Scilex Holding (SCLX) Q2 2026 earnings results →
Q2 2026 Revenue down 23% year over year to $7.6M · operating margin -385.0%
Scilex Holding made $7.6M in Q2 2026 (-23% Y/Y). Operating margin -385.0%, net loss $115M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.6M in Q2 2026, down 23% year over year and down 11% from the previous quarter.
Operating costs exceeded revenue by $29.4M, an operating margin of -385.0%. Total costs grew 22% against a revenue fall of 23%. The fastest-growing cost line was Other operating costs (+90%). The quarter ended with a net loss of $115.0M, wider than the previous quarter's $45.6M loss. Net interest and other expense of $85.6M was the main reason.
Operating cash flow was −$6.7M. Non-cash charges added back $2.8M of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items added $101.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $7.6M | -23% | -385.0% | −$115M | −$6.7M |
| Q1 2026 | 10-Q | May 20, 2026 | $8.6M | +72% | -373.5% | −$45.6M | −$1.1M |
| Q4 2025 | 10-K | Apr 10, 2026 | $4.8M | -68% | n/m | −$46.1M | −$17.5M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $10.6M | -27% | n/m | −$258M | $8.2M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $9.9M | -40% | -207.2% | −$44.0M | $7.0M |
| Q1 2025 | 10-Q | May 14, 2025 | $5.0M | -54% | -557.5% | −$26.1M | $6.0M |
| Q4 2024 | 10-K | Mar 31, 2025 | $14.9M | +11% | -190.5% | −$6.5M | $2.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
- DVLT — 26% of the supplier’s revenue · Stated in 10-K (sentence) · source
- CAH · Stated in 10-K (named, share not stated) · source
About Scilex Holding
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Our commercial products are: (i) ZTlido Ò (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S.
In its own words, from its 10-K, filed Apr 10, 2026.
Scilex Holding against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -23% against the peers' median +11%. Operating margin: -385.0% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SCLX Scilex Holding | Q2 2026 | $7.6M | -23% | -385.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Scilex Holding 10-Q on SEC EDGAR · CIK 1820190 · Biological Products, (No Diagnostic Substances)
13F: who owns SCLX and who is buying
More on SCLX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results